- Home
- OMDA vs RCUS Comparison
OMDA vs RCUS Comparison
Compare OMDA & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMDA
- RCUS
- Stock Information
- Founded
- OMDA 2011
- RCUS 2015
- Country
- OMDA United States
- RCUS United States
- Employees
- OMDA N/A
- RCUS N/A
- Industry
- OMDA Medical/Nursing Services
- RCUS Biotechnology: Pharmaceutical Preparations
- Sector
- OMDA Health Care
- RCUS Health Care
- Exchange
- OMDA Nasdaq
- RCUS Nasdaq
- Market Cap
- OMDA 1.2B
- RCUS 1.2B
- IPO Year
- OMDA 2025
- RCUS 2018
- Fundamental
- Price
- OMDA $22.26
- RCUS $11.75
- Analyst Decision
- OMDA Strong Buy
- RCUS Buy
- Analyst Count
- OMDA 7
- RCUS 8
- Target Price
- OMDA $24.86
- RCUS $20.71
- AVG Volume (30 Days)
- OMDA 377.0K
- RCUS 730.3K
- Earning Date
- OMDA 08-07-2025
- RCUS 11-05-2025
- Dividend Yield
- OMDA N/A
- RCUS N/A
- EPS Growth
- OMDA N/A
- RCUS N/A
- EPS
- OMDA N/A
- RCUS N/A
- Revenue
- OMDA $209,827,000.00
- RCUS $262,000,000.00
- Revenue This Year
- OMDA $43.43
- RCUS N/A
- Revenue Next Year
- OMDA $20.01
- RCUS N/A
- P/E Ratio
- OMDA N/A
- RCUS N/A
- Revenue Growth
- OMDA 135.27
- RCUS 6.07
- 52 Week Low
- OMDA $14.14
- RCUS $6.50
- 52 Week High
- OMDA $28.40
- RCUS $18.98
- Technical
- Relative Strength Index (RSI)
- OMDA N/A
- RCUS 63.14
- Support Level
- OMDA N/A
- RCUS $11.04
- Resistance Level
- OMDA N/A
- RCUS $12.05
- Average True Range (ATR)
- OMDA 0.00
- RCUS 0.56
- MACD
- OMDA 0.00
- RCUS 0.04
- Stochastic Oscillator
- OMDA 0.00
- RCUS 77.19
About OMDA Omada Health Inc. Common Stock
Omada Health Inc empowers individuals to make lasting health changes through personalized, virtual care between doctor's visits. The integrated platform of the company supports members with cardiometabolic conditions like prediabetes, diabetes, hypertension, musculoskeletal issues, and behavioral health needs. The company's specialized care tracks also assist members using GLP-1 medications. The Company delivers measurable health outcomes and value for employers, health plans, health systems, and pharmacy benefit managers.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.